Torsten Hoof — Senior Vice President of International at Genomic Health

Mr. Torsten Hoof joined Genomic Health, Inc. in 2017 as Senior Vice President, International, leading the company's international growth to ensure that the innovative suite of products and services to aid treatment decisions will provide benefit to many more patients and their health care providers around the world. Most recently, Torsten was the Vice President and Head of Oncology EMEA at Baxalta, where he built the company's oncology presence in Europe executing the European-wide launches of treatments for acute lymphocytic leukemia and ovarian cancer. Prior to Baxalta, Torsten was the European General Manager for Endocyte, where he established its European organization designed to bring an innovative, precision medicine solution to patients with ovarian cancer. Mr. Torsten Hoof is a Partner of Lumitereo. He involved in the IPO of Lion Bioscience as Vice President of Business Development and led the global launch of Tamiflu as Global Business Leader; Influenza at Roche. Mr. Hoof served as Vice President of Global Commercialization at Bristol-Myers Squibb. During his 10 years tenure as an Executive at Bristol-Myers Squibb, he led the global haemato-oncology franchise and, as EMEA General Manager and Vice President for HIV and Primary Care, he built strong teams, directed multiple launches and drove the growth of multi-billion dollar portfolios. In the earlier stages of his career with Roche, Torsten led the Tamiflu launch as a Global Business Leader and established Roche's German leadership position in Virology in the mid 90's. Torsten also served as an Independent Director at HRA Pharma until its acquisition by Goldman-Sachs/Astorg in 2016. Torsten holds a Master's degree with distinction in Biochemistry from the University of Hannover and his work on drug resistance in cancer was awarded with a Ph.D. by the same institution. Torsten is an Alumnus of the Boehringer Ingelheim Fonds.